Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight
NCT ID: NCT03187938
Last Updated: 2019-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
292 participants
OBSERVATIONAL
2017-06-14
2019-08-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determination of Maternal and Neonatal Apelinemia in Obese Women During Pregnancy
NCT02796456
Plasma Brain Natriuretic Peptide Levels in Pregnancy
NCT00324402
Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic Women
NCT05622838
First Trimester Prediction of Preeclampsia and Fetal Growth Restriction
NCT02379494
The Association Between Parathyroid Hormone and Preterm Labor
NCT05688007
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women at 24-28 weeks gestation
Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
Testing of Alkaline Phosphatase Levels
Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Testing of Alkaline Phosphatase Levels
Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known congenital malformations (any, except Pyelectasis)
* Chronic hypertension
* Inflammatory bowel disease (IBD)
* Gall bladder disease
* Active bone disease (ie, skeletal dysplasia, healing fracture)
* Active liver disease (ie, hepatitis, cholestasis, cholelithiasis (gallstones))
* Pre-existing type 1 and 2 Diabetes
* Early-onset IUGR
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TriHealth Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Donna Lambers, MD
Role: PRINCIPAL_INVESTIGATOR
TriHealth Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Good Samaritan TriHealth Hospital
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-095
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.